Abstract 2: Comparative Effectiveness and Safety of Anticoagulant Therapy With Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients With Nonvalvular Atrial Fibrillation [Session Title: Abstract Oral Session: QCOR 2016 Young Investigator Awards]
Conclusions: Our results demonstrated a lower risk of a thromboembolic event or stroke among dabigatran, apixaban, or rivaroxaban users compared to warfarin users. Among NOACs, risks of a thromboembolic event or stroke were similar. Further studies are needed to clarify the finding of a higher major bleeding risk in warfarin and rivaroxaban users.
Source: Circulation: Cardiovascular Quality and Outcomes - Category: Cardiology Authors: Adeboyeje, G., Sylwestrzak, G., White, J., Rosenberg, A., Abarca, J., Crawford, G., Barron, J. Tags: Session Title: Abstract Oral Session: QCOR 2016 Young Investigator Awards Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Coumadin | Databases & Libraries | Heart | Pradaxa | Stroke | Study | Warfarin